NEW YORK, Sept. 8 (GenomeWeb News) - Genstruct, a biological mechanism discovery company, said today that it has raised $6.5 million in a round of Series A financing.

Proceeds of the financing, the Cambridge, Mass.-based company said, will be used to expand its technical and business teams, build intellectual property around the company's enabling technology, and conduct internal discovery programs.

The financing was led by A. M. Pappas and Associates, which has placed managing partner Art Pappas on Genstruct's board, and Flagship Ventures.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.